The RGS9 gene provides instructions for making two versions (isoforms) of the RGS9 protein, known as RGS9-1 and RGS9-2. They are found in different parts of the nervous system and have very different functions.
RGS9-1 is produced in the retina, which is the specialized tissue at the back of the eye that detects light and color. Within the retina, RGS9-1 is associated with light-detecting cells called photoreceptors. When light enters the eye, it stimulates specialized pigments in these cells. This stimulation triggers a series of chemical reactions that produce an electrical signal, which is interpreted by the brain as vision. (This process is known as phototransduction.) Once photoreceptors have been stimulated by light, they must return to their resting state before they can be stimulated again. RGS9-1 is involved in a chemical reaction that helps return photoreceptors to their resting state quickly after light exposure.
RGS9-2 is found primarily in an area deep within the brain called the striatum. Although its exact role is unknown, RGS9-2 appears to be part of signaling pathways involving a chemical messenger (neurotransmitter) called dopamine. These pathways are important for planning and coordinating movement. Studies suggest that RGS9-2 also plays a role in the brain's response to opioid drugs, such as morphine and cocaine.
Health Conditions Related to Genetic Changes
At least two mutations in the RGS9 gene have been found to cause bradyopsia, a rare condition that affects vision. In people with bradyopsia, the eyes adapt more slowly than usual to changing light conditions (for example, walking out of a darkened movie theater into daylight or driving into a dark tunnel on a sunny day). Some affected individuals also have difficulty seeing small moving objects, such as a tennis ball.
The RGS9 gene mutations that cause bradyopsia greatly reduce or eliminate the function of RGS9-1 in photoreceptors. (These mutations do not appear to affect the function of RGS9-2 in the brain.) A loss of RGS9-1 function prevents photoreceptors from recovering quickly after responding to light. Normally they return to their resting state in a fraction of a second, but in people with RGS9 gene mutations, it can take ten seconds or longer. During that time, the photoreceptors cannot respond to light. This delay causes temporary blindness in response to changing light conditions and may interfere with seeing small objects when they are in motion.More About This Health Condition
Other Names for This Gene
- regulator of G-protein signaling 9
- regulator of G-protein signalling 9
Additional Information & Resources
Tests Listed in the Genetic Testing Registry
Scientific Articles on PubMed
Catalog of Genes and Diseases from OMIM
- Martemyanov KA, Arshavsky VY. Biology and functions of the RGS9 isoforms. Prog Mol Biol Transl Sci. 2009;86:205-27. doi: 10.1016/S1877-1173(09)86007-9. Epub 2009 Oct 7. Review. Citation on PubMed
- Michaelides M, Li Z, Rana NA, Richardson EC, Hykin PG, Moore AT, Holder GE, Webster AR. Novel mutations and electrophysiologic findings in RGS9- and R9AP-associated retinal dysfunction (Bradyopsia). Ophthalmology. 2010 Jan;117(1):120-127.e1. doi: 10.1016/j.ophtha.2009.06.011. Epub 2009 Oct 8. Citation on PubMed
- Nishiguchi KM, Sandberg MA, Kooijman AC, Martemyanov KA, Pott JW, Hagstrom SA, Arshavsky VY, Berson EL, Dryja TP. Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation. Nature. 2004 Jan 1;427(6969):75-8. Citation on PubMed
- Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ, Zachariou V. RGS9-2 is a negative modulator of mu-opioid receptor function. J Neurochem. 2007 Oct;103(2):617-25. Epub 2007 Aug 23. Citation on PubMed